Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Gastrointestinal Medicine
Volume 2017 (2017), Article ID 9343896, 4 pages
https://doi.org/10.1155/2017/9343896
Case Report

A Rare Case of Esophageal Adenocarcinoma with Urinary Bladder Metastasis

1Department of Hematology/Oncology, Joan C. Edwards School of Medicine, Marshall University, 1600 Medical Center Dr, Huntington, WV 25701, USA
2Department of Internal Medicine, Joan C. Edwards School of Medicine, Marshall University, 1600 Medical Center Dr, Huntington, WV 25701, USA
3Department of Pathology, Joan C. Edwards School of Medicine, Marshall University, 1600 Medical Center Dr, Huntington, WV 25701, USA

Correspondence should be addressed to Heather Katz

Received 17 March 2017; Accepted 14 May 2017; Published 31 May 2017

Academic Editor: Daniel C. Damin

Copyright © 2017 Heather Katz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Metastatic esophageal adenocarcinoma to the urinary bladder is extremely rare. We describe a previously healthy 49-year-old female with recent diagnosis of adenocarcinoma of the gastroesophageal junction with metastatic disease to the liver. Biopsy was positive for human epidermal growth factor receptor 2 (HER2) by Fluorescence In Situ Hybridization (FISH). She received six cycles of Cisplatin, 5-Fluorouracil, and Herceptin and subsequently developed symptomatic anemia and hematuria. Cystoscopy with retroflexion was performed and she received a transurethral resection of bladder tumor with fulguration. Pathology of the bladder tumor revealed similar morphology to her liver metastasis and immunohistochemical stains were consistent with metastatic esophageal cancer. Three weeks after being diagnosed with metachronous urinary bladder metastasis from esophageal adenocarcinoma primary, she expired. She only received her first cycle of palliative chemotherapy with Ramucirumab and Paclitaxel.